KKR & Co. Inc., 10% Owner at BridgeBio Pharma, Inc. (BBIO), sold 5,800,000 shares at $25.75 ($149.3M) on 2024-09-13, disclosed to the SEC on 2024-09-17.
Open-market sale of $149.3M BBIO by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| LAUR | SELL | 2022-11-22 | $618.1M | — | Filing → |
| APP | SELL | 2021-12-09 | $677.1M | — | Filing → |
| COTY | SELL | 2021-09-10 | $839.0M | — | Filing → |